Literature DB >> 11967565

Structural insights into CPT-11 activation by mammalian carboxylesterases.

Sompop Bencharit1, Christopher L Morton, Escher L Howard-Williams, Mary K Danks, Philip M Potter, Matthew R Redinbo.   

Abstract

Mammalian carboxylesterases cleave the anticancer prodrug CPT-11 (Irinotecan) into SN-38, a potent topoisomerase I poison, and 4-piperidino-piperidine (4PP). We present the 2.5 A crystal structure of rabbit liver carboxylesterase (rCE), the most efficient enzyme known to activate CPT-11 in this manner, in complex with the leaving group 4PP. 4PP is observed bound adjacent to a high-mannose Asn-linked glycosylation site on the surface of rCE. This product-binding site is separated from the catalytic gorge by a thin wall of amino acid side chains, suggesting that 4PP may be released through this secondary product exit pore. The crystallographic observation of a leaving group bound on the surface of rCE supports the 'back door' product exit site proposed for the acetylcholinesterases. These results may facilitate the design of improved anticancer drugs or enzymes for use in viral-directed cancer cotherapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967565     DOI: 10.1038/nsb790

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  40 in total

1.  Simulation on the structure of pig liver esterase.

Authors:  Daniel Hasenpusch; Uwe T Bornscheuer; Walter Langel
Journal:  J Mol Model       Date:  2010-09-24       Impact factor: 1.810

Review 2.  Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design.

Authors:  Toshihisa Ishikawa; Ai Tamura; Hikaru Saito; Kanako Wakabayashi; Hiroshi Nakagawa
Journal:  Naturwissenschaften       Date:  2005-10

3.  The Development of Bacterial Carboxylesterase Biological Recognition Elements for Cocaine Detection.

Authors:  Suhad A Mustafa
Journal:  Mol Biotechnol       Date:  2018-08       Impact factor: 2.695

Review 4.  Carboxylesterase inhibitors.

Authors:  M Jason Hatfield; Philip M Potter
Journal:  Expert Opin Ther Pat       Date:  2011-05-24       Impact factor: 6.674

Review 5.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

6.  Structural studies of a potent insect maturation inhibitor bound to the juvenile hormone esterase of Manduca sexta.

Authors:  Mark Wogulis; Craig E Wheelock; Shizuo G Kamita; Andrew C Hinton; Paul A Whetstone; Bruce D Hammock; David K Wilson
Journal:  Biochemistry       Date:  2006-04-04       Impact factor: 3.162

7.  Human carboxylesterase 1 stereoselectively binds the nerve agent cyclosarin and spontaneously hydrolyzes the nerve agent sarin.

Authors:  Andrew C Hemmert; Tamara C Otto; Monika Wierdl; Carol C Edwards; Christopher D Fleming; Mary MacDonald; John R Cashman; Philip M Potter; Douglas M Cerasoli; Matthew R Redinbo
Journal:  Mol Pharmacol       Date:  2010-01-05       Impact factor: 4.436

8.  In Silico Design and Evaluation of Carboxylesterase Inhibitors.

Authors:  Shana V Stoddard; Xiaozhen Yu; Philip M Potter; Randy M Wadkins
Journal:  J Pest Sci (2004)       Date:  2010       Impact factor: 5.918

9.  Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").

Authors:  M Jason Hatfield; Lyudmila G Tsurkan; Janice L Hyatt; Carol C Edwards; Andrew Lemoff; Cynthia Jeffries; Bing Yan; Philip M Potter
Journal:  J Nat Prod       Date:  2013-01-03       Impact factor: 4.050

10.  Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH).

Authors:  Craig E Wheelock; Kosuke Nishi; Andy Ying; Paul D Jones; Michael E Colvin; Marilyn M Olmstead; Bruce D Hammock
Journal:  Bioorg Med Chem       Date:  2007-11-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.